

Exploring Nanoscale Solutions in Healthcare

Manju Mathur ^[1], Apoorva Joshi ^[2], Naveen kumar ^[3], Nimesh Pareek ^[4]

^[1] Department of Computer Science and Engineering, global institute of technology, Jaipur

^[2] Department of Computer Science and Engineering, global institute of technology, Jaipur

^[3] Department of Computer Science and Engineering, global institute of technology, Jaipur

^[4] Department of Computer Science and Engineering, global institute of technology, Jaipur

ABSTRACT

Nanotechnology delves into the exploration of incredibly minute structures typically spanning from 1 to 100 nanometers. It marks a burgeoning realm of technological advancement with wide-ranging implications in human biology and medical science. Nanomedicine, a pivotal facet of the 21st century, endeavors to oversee, manipulate, and bolster all biological processes within the human body at the molecular scale. This pursuit relies on leveraging nanostructures and engineered instruments to furnish medical advantages. The applications of nanomedicine span diverse domains, encompassing diagnosis, surgical interventions, ocular care, neurological treatments, cancer therapies, and pharmaceutical delivery systems. Various nanocarriers, such as quantum dots, nanoparticles, dendrimers, carbon nanotubes, nanoshells, and nanocrystals, have been harnessed for diagnostic purposes. However, the utilization of nanomaterials gives rise to multifaceted environmental and societal apprehensions, particularly concerning toxicity issues. This review seeks to underscore the significant strides made by nanotechnology in modern healthcare while also delineating the opportunities and challenges within this domain. Furthermore, it delves into the environmental and societal ramifications stemming from its application in medical contexts.

Keywords – Magnetic Resonance Imaging, drug delivery, Nanotechnology.

I. INTRODUCTION

Advancements in nanotechnology have fundamentally altered the landscape of the 20th century, particularly within the fields of medicine and pharmaceuticals. Nanotechnology is dedicated to studying tiny entities known as nanoparticles, spanning dimensions from 0.1 to 100 nanometers, as depicted in (Figure 1). Due to their minute scale, nanoparticles exhibit distinctive characteristics such as magnetism, chemical reactivity, electrical conductivity, optical intricacies, and mechanical strength, which differ significantly from bulk materials. Nanotechnology operates through two primary methodologies: a top-down approach involves reducing larger structures to nano dimensions, while a bottom-up strategy entails assembling individual atoms and molecules into nanostructures. Modern nanotechnology represents an interdisciplinary frontier that explores the smallest particles and their unique physical, chemical, and mechanical attributes. nanotechnology melds principles from an array of disciplines including physics biology chemistry medicine electronics and information technology.




Fig 1: Nanoscale Biomolecules and Nanostructures

II. EVOLUTION OF NANOTECHNOLOGY

The progression of nanotechnology signifies an intriguing voyage of scientific exploration and technological progress. Originating as a theoretical notion introduced by physicist Richard Feynman in 1959, nanotechnology has evolved into a multidisciplinary realm with profound implications spanning various sectors. During the 1980s, the advent of the scanning tunneling microscope enabled scientists to manipulate and scrutinize individual atoms and molecules, establishing the foundation for manipulation at the nanoscale. This period marked the inception of nanoscience as researchers delved into the characteristics of

materials at the nanometer scale.

Table 1: Developments in Nanotechnology

Year	Development in the field of Nanotechnology
1902	Structures smaller than 4 nanometers detected in ruby glasses by Richard Zsigmondy and Henry Siedentopf
1931	Transmission electron microscope (TEM) by Max Knoll and Ernst Ruska
1936	Insight into the atomic range with the field electron microscope by Erwin Müller
1951	Development of field ion microscope (FIM)
1959	Concepts of nanotechnological approach by Richard Feynman
1960	Peter Paul Speiser-first nanoparticles used for targeted drug therapy
1974	The term nanotechnology -by Taniguchi for the first time.
1981	Gerd Binnig and Heinrich Rohrer - scanning tunneling microscope (STM)
1985	"Bucky Ball"
1986	First atomic force microscope (AFM) was commissioned
1989	IBM logo was made
1991	Carbon Nano tube for the first time by S. Iijima.
1999	Book by R. Freitas "Nano medicine" was published
2000	R.A. Freitas Jr- "nanodentistry"
2001	National Nanotechnology Initiative launched.
2003	Nanotechnology Research and Development Act
2004	First policy conference on advanced nanotech
2005-2010	3D Nano systems were prepared
2011	Era of molecular nano technology started
2012	NNI launched two more Nanotechnology Signature Initiatives (NSIs)
2016	Received Nobel Prize in Chemistry (for design and synthesis of molecular machines)
2017	Nobel Prize in Physics 2017: Gravitational waves.
2018	tic-tac-toe game board made with DNA. Shrinking objects to the nanoscale.

The 1990s witnessed significant advancements in nanotechnology, as novel fabrication methods such as molecular beam epitaxy and chemical vapor deposition emerged, facilitating precise manipulation of nanostructures. Concurrently, progress in computational modeling facilitated the creation of innovative nanomaterials with customized properties. With the onset of the 21st century, nanotechnology underwent a transition from primarily academic pursuit to a commercial enterprise, with industries making substantial investments in research and development. Breakthroughs in nanofabrication techniques, such as lithography and self-assembly, paved the path for large-scale production of nanomaterials and devices.

III. NANOTECHNOLOGY IN NANOMEDICINE AND DRUG DELIVERY

For ages, traditional herbal remedies have treated diverse ailments. These natural products offer numerous benefits, boasting various chemical and biological properties, specificity, low toxicity, and minimal side effects. They hold promise for discovering new drugs. Computational analyses aid in developing next-gen medications, facilitating target-oriented drug discovery and delivery mechanisms.

However, practical challenges arise when applying large-sized molecules in drug delivery. Despite their theoretical potential, many face obstacles in becoming effective drugs. These challenges underscore the complexities of nanoscale drug delivery, requiring innovative solutions. The issue with the practical use of those large-sized materials in drug delivery includes the following:

Limited solubility: The substance exhibits minimal solubility in water.

Limited bioavailability: Prior to reaching its target site, the substance undergoes degradation within the body, diminishing its bioavailability.

Limited absorption: Substances encounter challenges in traversing biological barriers like cell membranes, the blood-brain barrier, and the placenta.

Non-targeted delivery: Due to the absence of specificity towards a particular target, the substance is dispersed across various tissues and organs.

3.1. Pharmaceutical Design, Procedures and Mechanisms

Advancement in nanomedicine seeks to enhance drug specificity and diagnostic accuracy. This objective is driven by progress in drug discovery and delivery systems, supported by computational tools and experimental methodologies.

In developing targeted drug delivery systems, nanoparticles assume a crucial role in encapsulating drugs with poor solubility and limited absorption capabilities (refer to Figure 2). These nanoparticles, typically composed of various biodegradable materials such as natural or synthetic polymers, lipids, or metals, serve as the foundation for such systems. The effectiveness of these drug carriers depends on their biophysical and chemical characteristics, including size and shape. For instance, optimal polymeric nanomaterials for delivery systems range in diameter from 10 to 1000 nm. This size advantage allows nanoparticles to be efficiently internalized by cells compared to larger counterparts, thereby enhancing drug delivery efficiency. Polymeric nanoparticles can be further divided into nanoparticles and nanocapsules. Commonly used synthetic polymers (e.g., polyvinyl alcohol, poly-l-lactic acid, polyethylene glycol, and poly (lactic-co-glycolic acid)) and natural polymers (e.g., alginate and chitosan) offer excellent biocompatibility and biodegradability, making them ideal choices for nanoparticle fabrication. Among the most effective structures for targeted drug delivery are polymeric nanoparticles, compact lipid nanostructures, and phospholipid-based carriers such as liposomes and micelles.)




Fig 2: Drug delivery Mechanism (Untargeted and targeted delivery) [14]

3.2 Advances in Protein and Peptide Delivery Systems

Biopharmaceuticals encompass large molecules such as proteins and peptides utilized in the treatment of various diseases due to their multifaceted biological functions within living organisms. Nanomaterials offer a means for precise and regulated delivery of biopharmaceuticals. Nanoparticles and dendrimers are currently employed for this purpose.

3.3 Nanoparticles in Drug Delivery

Biopolymeric Nanoparticles

Biopolymeric nanoparticles utilize synthetic biodegradable polymers like polyalkylcyanoacrylate, poly(lactic-co-glycolic acid), and polyanhydride. Various biopolymeric substances possess therapeutic properties, hence their application in drug delivery systems. However, despite their therapeutic potential, delivering hydrophilic therapeutic molecules such as peptides, proteins, and nucleic acids via bionanoparticles presents a challenge. The issue stems from the hydrophobic nature of the polymers employed, which contrasts with the hydrophilicity of the therapeutic molecules. Consequently, ensuring the protection of drugs from enzymatic degradation proves challenging due to the inefficient encapsulation of drugs by these biopolymers.

Protein Nanoparticles

Nanoparticles were initially designed using two naturally occurring proteins, albumin and gelatin. These colloid systems based on proteins exhibit potential due to their low immunogenicity, non-toxicity, biodegradability, exceptional stability under storage and in vivo circumstances, and straightforward preparation, monitoring, and

scaling capabilities. Moreover, they facilitate surface alteration, thereby enabling the covalent binding of drugs subsequent to modification.

Albumin: Albumin is protein found in blood plasma that serves a variety of functions, including ligand transport, metabolism, and distribution, as well as antioxidant activity. Because of its role, it has been a staple in drug therapy for a considerable time. For instance, research has highlighted the utilization of altered serum albumin for specific tumor identification and removal of harmful substances. Nanomedicine has similarly capitalized on the capabilities of human serum albumin (HSA) and bovine serum albumin (BSA) as carriers for nanoparticle drug targeting, enhancers of therapy, and vehicles for modified drug delivery.

Gelatin: The process of partially hydrolyzing collagen results in the creation of a naturally occurring water-soluble macromolecule referred to as Type B gelatin. Gelatin offers numerous benefits, such as biocompatibility, biodegradability, lack of toxicity, non-irritating properties, low immunogenicity, and minimal antigenicity. Due to its suitability as a carrier molecule, gelatin has been employed in nanoparticle synthesis and drug delivery for more than thirty years.

Alginate: Alginate, a linear polysaccharide soluble in water, originates from brown seaweed. It comprises two uronic acids: α -L-guluronic acid and β -D-mannuronic acid. Its characteristics encompass biocompatibility, lack of immunogenicity, and mucosal adhesion. When combined with alginate, poly-L-lysine (PLL), a natural cationic polymer, creates bionanoparticles. Nevertheless, PLL poses toxicity and immunogenicity risks upon injection. Therefore, chitosan, another polysaccharide, serves as a substitute cationic polymer.

In addition to the above-mentioned natural polymer sources, nanomedicine makes use of higher plants, animals, microorganisms, and algae (Figure 3).




Fig 3: Various nanoparticles synthesised from Microorganisms

IV. NATURAL PRODUCT

BASED NANOTECHNOLOGY

Plants have long been a valuable source of natural therapeutic compounds, which have facilitated the discovery of highly effective drugs. In the present context, there has been a decline in the number of synthetic molecules being marketed, leading to increased research on active compounds derived from natural products. Some examples of such medicinal compounds obtained from plants include alkaloids, flavonoids, tannins, terpenes, saponins, steroids, and phenolic compounds (Figure 4). However, these compounds also possess certain drawbacks, such as high systemic clearance, requiring repeated or high doses, as well as low absorption capacity, resulting in reduced bioavailability and efficacy. Nevertheless, nanotechnology offers a promising solution to these challenges.




Fig 4: Natural compounds extracted from higher plants used in Nano medicine [14]

Natural products like microbes and plant extracts can be used to synthesize nanoparticles. For example, it can be synthesized extracellularly or intracellularly using a variety of microorganisms such as bacteria, fungi, algae, and yeast. Plant extract can also be used to synthesize nanoparticles by mixing it with a metal precursor. Then incubate it for the required amount of time at room temperature, while being exposed to light [14].

V. NANOTECHNOLOGY IN DISEASES

5.1 Nanotechnology in cancer

Nanoparticles have found extensive application in the treatment of various diseases, with cancer treatment being particularly notable [5]. Cancer, as a challenging disease, presents unique difficulties when it comes to brain cancer, which is considered the most formidable form of cancer. The challenges related to imaging and administering therapeutic agents across the blood-brain barrier into the brain have historically posed significant hurdles. However, nanotechnology has emerged as a

valuable asset in surmounting these challenges by efficiently navigating the blood-brain barrier and releasing anti-cancer drugs bound to nanomaterials, such as loperamide and doxorubicin, at therapeutic levels. In the field of cancer therapy, iron nanoparticles or gold shells are frequently employed for this purpose.

5.2 Nanotechnology in Angiogenesis

To treat cancer, antiangiogenic agents must be used to inhibit angiogenesis. A research team led by Sengupta and collaborators emphasized the significant influence of disrupting tumor blood vessels on the delivery of chemotherapeutic agents. The process of angiogenesis is governed by integrin $\alpha\beta_3$ and vascular endothelial growth factors (VEGF), making them prime targets for nanoparticle-based inhibition of angiogenesis. In this innovative approach to anti-angiogenesis, self-assembling rosette nanotubes (RGDSK-RNT) loaded with FITC-GRGDS were employed to monitor and dismantle blood vessels adjacent to the tumor. Consequently, these RNTs demonstrate efficacy in controlling disease progression by targeting cell adhesion molecules and vascular endothelial growth factor.

5.3 Nanotechnology in HIV/AIDS

Targeting the HIV-1 Tat protein presents a promising avenue for combating HIV/AIDS, with researchers focusing on vaccine development against this particular protein. However, delivering the HIV-1 protease inhibitor CGP 70726 poses challenges due to its poor water solubility. To surmount this obstacle, pH-sensitive nanoparticles containing CGP 70726 and benzyl alcohol were employed for protease inhibitor delivery. This strategy was successfully tested in canine subjects, with blood sample analysis confirming efficient drug release. Additionally, in a separate investigation, Solid Lipid Nanoparticles (SLNs) loaded with DNA and Tat peptide were administered to the lungs of mice, resulting in successful transfection, albeit with some DNA degradation observed. Despite notable achievements in drug delivery for cancer and neurodegenerative diseases, progress in HIV/AIDS treatment remains relatively slower. However, by dedicating more efforts to in vitro studies in this domain, we can address this discrepancy and advance HIV/AIDS treatment.

5.4 Nanotechnology in Respiratory diseases

Nanoparticles have not been widely utilized in the process of delivering medication for the treatment of respiratory illnesses. However, there exists a myriad of examples in literature showcasing therapies aimed at combating infectious respiratory diseases such as tuberculosis (TB), as well as allergic and genetic respiratory ailments [10]. Among these therapies, nanotechnology stands out

as a particularly promising approach for tackling TB. This is due to the fact that anti-TB drugs can be successfully encapsulated and delivered with the aid of nanotechnology [1].

5.5. Nanotechnology in Neurodegenerative diseases

Nanotechnology is widely used in the treatment of neurodegenerative disorders. Dendrimers, nano gels, nano emulsions, liposomes, polymeric nano particles, solid lipid nano particles, and nano suspensions have all been extensively studied as nanocarriers for CNS therapeutic delivery [1].

Parkinson's disease: Following Alzheimer's disease, Parkinson's disease (PD) ranks as the second most prevalent neurodegenerative disorder, affecting one out of every hundred people over the age of 65. Parkinson's disease is a central nervous system disease characterised by neuroinflammatory responses that cause severe difficulties with body motion. Current therapies aim to improve the patient's functional capacity for as long as possible while not altering the progression of the neurodegenerative process. Applied nanotechnology aims to regenerate and protect the central nervous system (CNS). Efforts are being made to develop novel technologies that, directly or indirectly, aid in neuroprotection, a permissive environment, and active signalling cues for guided axon growth. To reduce the peripheral side effects of traditional Parkinson's disease therapies, research is focusing on the design, biometric simulation, and optimization of an intracranial nano-enabled scaffold device (NESD) for site-specific dopamine delivery to the brain as a strategy [1].

5.6 Nanotechnology in Ophthalmology

Ophthalmology is a medical specialty that focuses on diagnosing and treating eye disorders. In ophthalmology, nanotechnology finds application in addressing various issues such as oxidative stress treatment, intraocular pressure measurement, scar prevention post glaucoma surgery, and treatment of retinal degenerative diseases. This includes utilizing gene therapy, prosthetics, theragnostics, and nanoparticles for managing choroidal neovascularization, alongside regenerative nanomedicine techniques. A new Nanoscale Dispersed Eye Ointment (NDEO) has been successfully developed to treat severe evaporative dry eye. Several studies have demonstrated the use of various nanoparticulate systems in ocular drug delivery, including microemulsions, nanosuspensions, nanoparticles, liposomes, niosomes, dendrimers, and cyclodextrins [1].

5.7 Nanotechnology and Antibiotic resistance

Nanoparticles can help reduce antibiotic resistance in combination therapy. Zinc oxide nanoparticles have been shown to reduce antibiotic resistance and increase Ciprofloxacin's antibacterial activity against microorganisms by interfering with various proteins involved in antibiotic resistance or drug pharmacology [1].

VI. ETHICS

Science provides numerous fascinating areas for research. One of them is the science of nanomedicine (nanotechnology), which has received a lot of attention over the last two decades. This is because extensive research has been conducted in this field, resulting in the successful completion of numerous clinical trials and the filing of nearly 1500 patents [14]. Thus, it is clear that in the coming decade, nanotechnology applications will broaden and gain importance in medicine and medical technology [3]. At the same time, it is critical to thoroughly examine the ethical, legal, and social implications of this emerging technology. In this review, let us consider the standards and regulations set by the ethics committees on a European scale. As a result, it is clear that a thorough analysis is required based on the following principles [4]:

- ✓ **Non-instrumentalisation:** Individuals should not be treated as means, but as ends in themselves
- ✓ **Privacy:** It is crucial to uphold confidentiality and respect an individual's right to privacy at all times.
- ✓ **Non-discrimination:** Every person deserves equal treatment, regardless of gender, race, colour, language, or any other discriminatory factor. Unless there are valid reasons for the difference in treatment.
- ✓ **Informed consent:** Obtaining prior permission from individuals is essential before conducting any medical or research intervention.
- ✓ **Equity:** Every person should have a fair access to the benefits under consideration
- ✓ **The Precautionary Principle:** This principle imposes a moral obligation to continuously assess the risks associated with new technologies.

VII. CONCLUSION

This review underscores the potential of nanoparticles as versatile tools in drug and gene delivery, biomedical imaging, diagnostics, biosensors, cancer therapies, tissue engineering, and various other applications. Nanotechnology holds immense promise due to its capacity to integrate with biology-based technologies, leading to the emergence of innovative hybrid approaches

aimed at enhancing human life across multiple dimensions. Nanomedicine has gained traction in recent times owing to its capability to target specific cells using nanobots, thereby minimizing damage to healthy tissue during drug delivery. Researchers are exploring diverse nanomaterials to enhance the intelligence of nanocarriers for drug and gene delivery by studying their physicochemical and biological properties. Nanomaterials, functioning as nanosensors, exhibit unique properties enabling the production of high-resolution images of tumors. While significant strides have been made in nanomedicine, much of the focus has centered on cancer diagnosis and treatment. This imbalance is anticipated to be rectified in the forthcoming years through comprehensive research spanning all realms of medicine.

REFERENCES

- [1] Nikalje, A. P.(2015) “Nanotechnology and its Applications in Medicine.” *Medicinal Chemistry* 5; 1-9.
- [2] Abdussalam-Mohammed, W. (2019). Review of Therapeutic Applications of Nanotechnology in Medicine Field and its Side Effects. *Journal of Chemical Reviews*, 1(3), 243-251. doi: 10.33945/SAMI/JCR.2019.3.5
- [3] Krukemeyer, M.G., Krenn, Hübner, F., Wagner, W., & Resch, R. (2015). History and Possible Uses of Nanomedicine Based on Nanoparticles and Nanotechnological Progress. *Journal of Nanomedicine & Nanotechnology*, 6, 1-7. <https://doi.org/10.4172/2157-7439.1000336>
- [4] Patrick Boisseau a.,Bertrand Loubaton.(2011). Nanomedicine, nanotechnology in medicine, C. R. Physique 12, 620–636. <https://doi.org/10.1016/j.crhy.2011.06.001>
- [5] Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., Bosi, S., Carril, M., Chan, W. C., Chen, C., Chen, X., Chen, X., Cheng, Z., Cui, D., Du, J., Dullin, C., Parak, W. J. (2017).
- [6] Zuo, L., Wei, W., Morris, M., Wei, J., Gorbounov, M., & Wei, C. (2007). New technology and clinical applications of nanomedicine. *The Medical clinics of North America*, 91(5), 845–862. <https://doi.org/10.1016/j.mcna.2007.05.004>
- [7] Shrivastava, S.S., & Dash, D. (2009). Applying Nanotechnology to Human Health: Revolution in Biomedical Sciences. *Journal of Nanotechnology*, 2009, 1-14. <https://doi.org/10.1155/2009/184702>
- [8] Srilatha B (2016). A review on Nanotechnology and nanomedicine. *journal of pharmaceutics and Nanotechnology*, 7.
- [9] Murthy S. K. (2007). Nanoparticles in modern medicine: state of the art and future challenges. *International journal of nanomedicine*, 2(2), 129–141.
- [10] Andreou, C., Pal, S., Rotter, L., Yang, J., & Kircher, M. F. (2017). Molecular Imaging in Nanotechnology and Theranostics. *Molecular imaging and biology*, 19(3), 363–372. <https://doi.org/10.1007/s11307-017-1056z>
- [11] Kim, J., Lee, N., & Hyeon, T. (2017). Recent development of nanoparticles for molecular imaging. *Philosophical transactions. Series A, Mathematical, physical, and engineering sciences*, 375(2107), 20170022. <https://doi.org/10.1098/rsta.2017.0022>
- [12] Suri, Sarabjeet & Fenniri, Hicham & Singh, Baljit. (2007). Nanotechnology-based Drug Delivery Systems. *Journal of occupational medicine and toxicology (London, England)*. 2. 16. <https://doi.org/10.1186/1745-6673-2-16>
- [13] Patra, J. K., Das, G., Fraceto, L. F., Campos, E., Rodriguez-Torres, M., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H. S. (2018). <https://doi.org/10.1186/s12951-018-0392-8>
- [14] Salata O. (2004). Applications of nanoparticles in biology and medicine. *Journal of nanobiotechnology*, 2(1), 3. <https://doi.org/10.1186/1477-3155-2-3>
- [15] Aced, Khalid & Khan, Idrees. (2017). Nanoparticles: Properties, Applications and Toxicities. *Arabian Journal of Chemistry*. 12(7), 908-931. <https://doi.org/10.1016/j.arabjc.2017.05.011>
- [16] Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., & Rizzolio, F. (2019). The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine. *Molecules (Basel, Switzerland)*, 25(1), 112. <https://doi.org/10.3390/molecules25010112>
- [17] Singh, S., & Singh, A. (2013). Current status of nanomedicine and nanosurgery. *Anesthesia, essays and researches*, 7(2).
- [18] Gaurav Kumar Soni, Dinesh Yadav, Ashok Kumar, “Design consideration and recent

- developments in flexible, transparent and wearable antenna technology: A review”, Transactions on Emerging Telecommunication Technologies, Vol. 35, Issue. 1, e4894, pp. 1-28, 2024.
- [19] Gaurav Kumar Soni, Dinesh Yadav, Ashok Kumar, “Flexible and Wearable Antenna Design for Bluetooth and Wi-Fi Application”, International Journal of Electrical and Electronics Research, Vol. 12, Special Issue –BDF, pp. 36-41, 2024.
- [20] G. K. Soni, A. Rawat, D. Yadav and A. Kumar, "2.4 GHz Antenna Design for Tumor Detection on Flexible Substrate for On-body Biomedical Application," 2021 IEEE Indian Conference on Antennas and Propagation (InCAP), pp. 136-139, 2021. doi: 10.1109/InCAP52216.2021.9726323.
- [21] G. Shankar, G. K. Soni, B. Kumar Singh and B. B. Jain, "Tunable Low Voltage Low Power Operational Transconductance Amplifier For Biomedical Application," IEEE 2021 Fourth International Conference on Electrical, Computer and Communication Technologies (ICECCT), pp. 1-6, 2021. doi: 10.1109/ICECCT52121.2021.9616627.
- [22] G. K. Soni, H. Singh, H. Arora and A. Soni, "Ultra Low Power CMOS Low Pass Filter for Biomedical ECG/EEG Application," 2020 Fourth International Conference on Inventive Systems and Control (ICISC), pp. 558-561, 2020.
- [23] G. K. Soni and H. Arora, "Low Power CMOS Low Transconductance OTA for Electrocardiogram Applications", Recent Trends in Communication and Intelligent Systems. Algorithms for Intelligent Systems, pp. 63-69, 2020. https://doi.org/10.1007/978-981-15-0426-6_7
- [24] G.K. Soni, A. Rawat, S. Jain and S.K. Sharma, "A Pixel-Based Digital Medical Images Protection Using Genetic Algorithm with LSB Watermark Technique", Springer Smart Systems and IoT: Innovations in Computing. Smart Innovation Systems and Technologies, vol. 141, pp 483–492, 2020.
- [25] Pradeep Jha, Deepak Dembla & Widhi Dubey , “Implementation of Transfer Learning Based Ensemble Model using Image Processing for Detection of Potato and Bell Pepper Leaf Diseases”, International Journal of Intelligent Systems and Applications in Engineering, 12(8s), 69–80, 2024.
- [26] Pradeep Jha, Deepak Dembla & Widhi Dubey, “Deep learning models for enhancing potato leaf disease prediction: Implementation of transfer learning based stacking ensemble model”, Multimedia Tools and Applications, Vol. 83, pp. 37839–37858, 2024.
- [27] Bhatia, Pramod; Garg, Vivek et al. (Patent No: 20 2022 102 590.8) (2022) Intelligent seating system based on IoT and machine learning. .
- [28] Pradeep Jha, Deepak Dembla & Widhi Dubey , “Crop Disease Detection and Classification Using Deep Learning-Based Classifier Algorithm”, Emerging Trends in Expert Applications and Security. ICETEAS 2023. Lecture Notes in Networks and Systems, vol 682, pp. 227-237, 2023.
- [29] P. Jha, D. Dembla and W. Dubey, "Comparative Analysis of Crop Diseases Detection Using Machine Learning Algorithm," 2023 Third International Conference on Artificial Intelligence and Smart Energy (ICAIS), Coimbatore, India, 2023, pp. 569-574, doi: 10.1109/ICAIS56108.2023.10073831.
- [30] P. Jha, R. Baranwal, Monika and N. K. Tiwari, "Protection of User's Data in IOT," 2022 Second International Conference on Artificial Intelligence and Smart Energy (ICAIS), Coimbatore, India, 2022, pp. 1292-1297, doi: 10.1109/ICAIS53314.2022.9742970.
- [31] Mehra, M., Jha, P., Arora, H., Verma, K., Singh, H. (2022). Salesforce Vaccine for Real-Time Service in Cloud. In: Shakya, S., Balas, V.E., Kamolphiwong, S., Du, KL. (eds) Sentimental Analysis and Deep Learning. Advances in Intelligent Systems and Computing, vol 1408. Springer, Singapore. https://doi.org/10.1007/978-981-16-5157-1_78
- [32] P. Jha, D. Dembla and W. Dubey, “Implementation of Machine Learning Classification Algorithm Based on Ensemble Learning for Detection of Vegetable Crops Disease”, International Journal of Advanced Computer Science and Applications, Vol. 15, No. 1, pp. 584-594, 2024.
- [33] P. Jha, T. Biswas, U. Sagar and K. Ahuja, "Prediction with ML paradigm in Healthcare System," 2021 Second International Conference on Electronics and Sustainable Communication Systems (ICESC), Coimbatore, India, 2021, pp. 1334-1342, doi: 10.1109/ICESC51422.2021.9532752.